medigraphic.com
ISSN 0016-3813 (Impreso)

2008, Número 3

<< Anterior Siguiente >>

Gac Med Mex 2008; 144 (3)


Actividad del factor VIII en jóvenes mexicanos con infarto agudo del miocardio

Majluf-Cruz A, Moreno-Hernández M, Martínez-Esquivel N, Ruiz de Chávez-Ochoa AA, Coria-Ramírez É, Monroy-García R, Vela-Ojeda J, García-Chávez J, Basave-Rojas M, Villasís-Keever MÁ

Idioma: Español
Referencias bibliográficas: 51
Paginas: 199-206
Archivo PDF: 68.69 Kb.


RESUMEN

Antecedentes: La enfermedad aterotrombótica es la causa de muerte más frecuente y la mayoría corresponde a infarto agudo del miocardio (IAM). Los menores de 45 años representan 5 a 10% de los IAM y es común que no sean portadores de factores de riesgo aterotrombótico clásicos.
Métodos: Este estudio transversal analítico incluyó pacientes menores de 45 años con IAM, de uno y otro sexo, pareados por edad, sexo y grupo sanguíneo con sus respectivos controles, para analizar el impacto de diferentes factores de riesgo aterotrombótico sobre el IAM. Incluimos 160 casos y controles, 77 hombres y 83 mujeres.
Resultados: El 25% de los pacientes tuvo aumento del factor VIII de la hemostasia (FVIII) vs. 8.8% en los controles. El FVIII promedio para pacientes y controles fue 134 mg/dl (IC 95%=114) vs. 118 mg/dl (IC 95%=128-140), respectivamente (p=0.001). La prevalencia de actividad alta del FVIII fue mayor que la de diabetes mellitus o hipertensión arterial. Paradójicamente, el colesterol HDL fue mayor en los pacientes que en los controles. Las únicas variables cuantitativas asociadas a IAM fueron la actividad alta del FVIII, la cuenta de monocitos en sangre periférica y el colesterol HDL.
Conclusiones: Los factores de riesgo aterotrombótico clásicos no explican totalmente el IAM en jóvenes. El aumento de FVIII es un factor de riesgo moderado pero frecuente en la población joven con IAM.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Organización Panamericana de la Salud. Las condiciones de la salud en las Américas. Enfermedades y daños a la salud. Washington, DC: OPS; 1994;vol.1.

  2. National Heart, Lung and Blood Institute. NHLBI Fact Book, Fiscal Year 1995. US Department of Health and Human Services, National Institutes of Health; 1996.

  3. Tavazzi L. Clinical epidemiology of acute myocardial infarction. Am Heart J 1999;138:S48-S54.

  4. Miettinen H, Salomaa V, Ketonen M, Niemela M, Immonen-Räihä P, Mähönen M. Trends in the treatment of patients with myocardial infarction and coronary revascularization procedures in Finland during 1986-92: the FINMONICA Myocardial Infarction Register Study. J Intern Med 1999;245:11-20.

  5. Rosamond WD, Chambless LE, Folson AR, Cooper LS, Conwill DE, Clegg L, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-867.

  6. National Heart, Lung and Blood Institute. Morbidity and mortality hartbook on cardiovascular, lung and blood diseases/1996. US Department of Health and Human Services; 1996.

  7. Alpert JS. Myocardial infarction with angiographically normal coronary arteries. Arch Intern Med 1994;154:265-269.

  8. Kyriakidis M, Androulakis A, Triposkiadis P, Tentolouris K, Vardinoyannis V, Copsari C, et al. Lack of a thrombotic tendency in patients with acute myocardial infarction and angiographically normal coronary arteries. Cardiology 1995;86:22-24.

  9. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.

  10. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham. Statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-1887.

  11. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996;27:978-990.

  12. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein (α), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-386.

  13. O’Donnell J, Mumford AD, Maninng RA, Laffan M. Elevation of factor VIII: C in venous thromboembolism is persistent and independent of acute phase response. Thromb Haemost 2000;83:10-13.

  14. Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings angina and blood groups in middle aged men. Thromb Haemost 1977;38:874-880.

  15. Haines AP, Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983;50:800-803.

  16. Meade TW, Cooper JA, Stirling DJ, Howarth DJ, Ruddock V, Miller GJ. Factor VIII ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994;88:601-607.

  17. Cortellano M, Boschetti C, Cifrancesco E. The PLAT Study: a multidisciplinary study of hemostatic function and convertional risk factors in vascular disease patients. Atherosclerosis 1991;90:109-118.

  18. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999;105:110-116.

  19. US Department of Health and Human Services. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 03-5233. NIH; 2003.

  20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(Suppl 1):S37-S42.

  21. International Diabetes Federation. The IDF Consensus Worldwide definition of the metabolic syndrome. April 14th, 2005.

  22. Marder VJ, Mannucci PM, Firkin BG, Hoger LW. Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committe on Thrombosis and Haemostasis. Thromb Haemost 1985;54:871-872.

  23. Mejía-Aguirre JM, Fajardo-Gutiérrez A, Gómez-Delgado A, Cuevas-Urióstegui ML, Hernández-Hernández DM, Garduño-Espinoza J. El tamaño de muestra: un enfoque práctico en la investigación clínica pediátrica. Bol Med Hosp Infant Mex 1995;52:381-391.

  24. Libby P. Molecular bases of the acute coronary syndrome. Circulation 1995;91:2844-2850.

  25. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250, 310-318.

  26. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998;19 (Suppl C):C39-C43.

  27. Wirtz PH, Ehlert U, Emini L, Rüdisüli K, Groessbauer S, von Känel R. Procoagulant stress reactivity and recovery in apparently healthy men with systolic and diastolic hypertension. J Psychosom Res 2007;63:51-58.

  28. Braunwald E. Coronary spasm and acute myocardial infarction: new possibility for treatment and prevention. N Engl 1978;299:1301-1303.

  29. Bergeron G, Goldsmith R, Schiller N. Myocardial infarction, severe, reversible ischemia and shock following excess thyroid administration in women with normal coronary arteries. Arch Intern Med 1988;148:1450-1453.

  30. Kopelson G, Herwing K. The etiologies of coronary artery disease in cancer patients. Int J Radiat Oncol Biol Phys 1978;4:895-906.

  31. Yeager S, Freed M. Myocardial infarction as a manifestation of polycytemia vera in cyanotic heart disease. Am J Cardiol 1984;53:952-953.

  32. Waller B. Cardiopatía coronaria no aterosclerosa. En: Fuster V, Alexander RW, O’Rourke RA, eds. El corazón. 10a. edición. Madrid, España: McGraw Hill-Interamericana; 2002. pp. 1195-1239.

  33. Lobato-Mendizabal E, Majluf-Cruz A. Trombofilia, tromboembolia y el uso de las heparinas no fraccionadas y de bajo peso molecular. Rev Invest Clin 2000;56:346-365.

  34. Rao AK, Kaplan R, Sheth S. Inherited thrombophilic states. Semin Thromb Hemost 1998;24:3-12.

  35. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE. Sudden cardiac death. Support for a role of triggering in causation. Circulation 1993;87:1442-1450.

  36. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular disease and nonvascular mortality. JAMA 2005;294:1799-1809.

  37. Merlini P, Bauer K, Oltrona L, Ardissimo D, Cattaneo M. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.

  38. Rosendaal FR. Risk factors for venous thromboembolic disease. Thromb Haemost 1999;82:610-619.

  39. Hernández-Jerónimo J, Maradamas-Zárate C, Pérez-Campos E, Majluf-Cruz A. Un nuevo factor de riesgo trombofílico. El incremento en el FVIII de la coagulación. Rev Invest Clin 2003;55:448-457.

  40. Rosendaal FR, Varekam I, Smith C, Brocker-Vriends HJT, Van Dijck H. Mortality and causes of death in Dutch haemophiliacs A, 1973-86. Br J Haematol 1989;71:71-76.

  41. LickfettL, Hagendorff A, Jung W, Pizzulli L, Brackmann HH, Luderitz B. Acute posterior wall infarct after factor VIII concentrate administration to patient with severe hemophilia A. Deustche Med Woch 1998;123:658-662.

  42. Kernoff LM, Rose AG, Hughes J, Jacobs P. Autopsy findings in an elderly man suffering from severe von Willebrand’s disease. Thromb Haemost 1981;46:714-716.

  43. Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993;70:758-761.

  44. Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GC, Davis K, et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 1993;81:2644-2651.

  45. Rice GI, Grant PJ. Factor VIII coagulant activity and antigen in subjects with ischaemic heart disease. Thromb Haemost 1998;80:757-762.

  46. Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease I: Abnormalities in factor VIII and antithrombin. Thromb Res 1982;26:183-192.

  47. Haines AP, Howarth D, North WRS. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983;50:800-803.

  48. Stringer MD, Kakkar W. Markers of disease severity in peripheral atherosclerosis. Eur J Vasc Surg 1990;4:513-518.

  49. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII:C in acute cerebrovascular disease: relationship to stroke subtype and mortality. Thromb Haemost 1997;77:1104-1108.

  50. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects. Arterioscler Thromb Vasc Biol 1999;19:3071-3078.

  51. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89-101.




2020     |     www.medigraphic.com